Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Eli Lilly and Co Stock Research

LLY

550.13USD-19.51(-3.42%)Market Closed
Watchlist

Market Summary

USD550.13-19.51
Market Closed
-3.42%

LLY Alerts

  • 3 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

LLY Stock Price

LLY RSI Chart

LLY Valuation

Market Cap

495.0B

Price/Earnings (Trailing)

76.18

Price/Sales (Trailing)

16.77

EV/EBITDA

56.28

Price/Free Cashflow

86.22

LLY Price/Sales (Trailing)

LLY Profitability

EBT Margin

22.69%

Return on Equity

50.82%

Return on Assets

10.7%

Free Cashflow Yield

1.16%

LLY Fundamentals

LLY Revenue

Revenue (TTM)

29.5B

Revenue Y/Y

28.11%

Revenue Q/Q

19.43%

LLY Earnings

Earnings (TTM)

6.5B

Earnings Y/Y

85.11%

Earnings Q/Q

31.1%

Price Action

52 Week Range

299.13601.84
(Low)(High)

Last 7 days

-7.0%

Last 30 days

-0.6%

Last 90 days

19.9%

Trailing 12 Months

86.1%

LLY Financial Health

Current Ratio

1.3

LLY Investor Care

Dividend Yield

1.06%

Dividend/Share (TTM)

5.83

Buy Backs (1Y)

0.07%

Diluted EPS (TTM)

7.19

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for LLY

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-18
Hedley Mary Lynne
acquired
9,711
571
17.00
-
2023-09-18
Alvarez Ralph
acquired
11,425
571
20.00
-
2023-09-18
Fyrwald J Erik
acquired
9,711
571
17.00
-
2023-09-18
LUCIANO JUAN R
acquired
14,282
571
25.00
-
2023-09-18
JOHNSON KIMBERLY H
acquired
9,711
571
17.00
-
2023-09-18
Sulzberger Gabrielle
acquired
5,141
571
9.00
-
2023-09-12
Weems Alonzo
gifted
-
-
-760
evp, erm & ceco
2023-09-12
Weems Alonzo
sold
-678,445
590
-1,148
evp, erm & ceco
2023-09-07
LILLY ENDOWMENT INC
sold
-119,995,000
571
-210,000
-
2023-08-31
Dozier Eric
gifted
-
-
-546
evp, hr & diversity

1–10 of 50

Which funds bought or sold LLY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-19
BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL
reduced
-2.44
1,915,870
7,681,890
3.22%
2023-09-14
Proquility Private Wealth Partners, LLC
sold off
-100
-913,353
-
-%
2023-09-13
CGC Financial Services, LLC
new
-
1,876
1,876
-%
2023-09-12
Prosperity Financial Group, Inc.
added
5.87
205,928
667,828
0.59%
2023-09-12
Farther Finance Advisors, LLC
added
385
1,413,960
1,665,350
0.36%
2023-09-12
Prosperity Wealth Management, Inc.
new
-
214,355
214,355
0.14%
2023-09-08
TUCKER ASSET MANAGEMENT LLC
added
308
318,006
387,377
0.11%
2023-09-07
ST GERMAIN D J CO INC
new
-
798,204
798,204
0.04%
2023-09-07
JAG CAPITAL MANAGEMENT, LLC
added
26.72
6,148,770
14,565,700
1.68%
2023-09-07
Strategic Financial Concepts, LLC
added
4.22
86,199
289,867
0.11%

1–10 of 46

Latest Funds Activity

Are funds buying LLY calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own LLY
No. of Funds

Schedule 13G FIlings of Eli Lilly and

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
7.73%
73,429,863
SC 13G/A
Feb 01, 2023
blackrock inc.
6.9%
65,467,793
SC 13G/A
Jan 25, 2023
lilly endowment inc
10.83%
102,948,810
SC 13G/A
Feb 11, 2022
pnc financial services group, inc.
5.42%
51,888,455
SC 13G/A
Feb 09, 2022
vanguard group inc
7.24%
69,261,754
SC 13G/A
Feb 08, 2022
blackrock inc.
6.7%
63,877,023
SC 13G/A
Jan 27, 2022
lilly endowment inc
11.23%
107,463,810
SC 13G/A
Feb 12, 2021
pnc financial services group, inc.
5.44%
52,012,151
SC 13G/A
Feb 10, 2021
vanguard group inc
7.18%
68,661,494
SC 13G/A
Jan 29, 2021
blackrock inc.
6.1%
58,811,768
SC 13G/A

Recent SEC filings of Eli Lilly and

View All Filings
Date Filed Form Type Document
Sep 20, 2023
4
Insider Trading
Sep 20, 2023
4
Insider Trading
Sep 20, 2023
4
Insider Trading
Sep 20, 2023
4
Insider Trading
Sep 20, 2023
4
Insider Trading
Sep 20, 2023
4
Insider Trading
Sep 13, 2023
4
Insider Trading
Sep 12, 2023
144
Notice of Insider Sale Intent
Sep 08, 2023
4
Insider Trading
Sep 07, 2023
144
Notice of Insider Sale Intent

Peers (Alternatives to Eli Lilly and)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
495.0B
29.5B
-0.64% 86.07%
76.18
16.77
1.53% 14.16%
420.1B
97.8B
-2.63% 0.36%
32.18
4.3
2.29% -28.92%
272.8B
58.3B
-0.47% 27.98%
17.88
4.63
2.00% -81.24%
185.5B
77.9B
-10.83% -24.56%
8.64
2.38
-23.04% -26.74%
150.1B
45.2B
-4.49% -14.30%
23.72
3.25
-4.15% 20.34%
MID-CAP
6.5B
-
1.73% 596.48%
-74.02
4.1K
-86.94% 71.24%
4.4B
4.6B
-13.48% -15.45%
-65.31
0.95
6.60% 42.04%
SMALL-CAP
1.6B
627.1M
-7.75% -19.97%
-1.08
2.5
-0.20% -204.67%
1.5B
634.0M
-13.44% -19.42%
34.58
2.36
0.62% -24.59%
843.4M
244.3M
-2.42% 7.48%
4.28
3.45
-39.50% -4.99%
807.9M
109.5M
20.45% -29.10%
-5.63
7.38
-2.66% -32.13%
482.6M
31.2M
-9.55% -49.48%
-4.58
15.49
407.54% -26.47%
422.3M
453.3M
90.89% -73.90%
-0.34
0.93
-16.04% 55.90%
258.3M
54.6M
-16.41% -43.89%
-2.85
4.73
9.39% -179.16%
-
2.2B
- -
-
-
-22.39% 63.59%

Eli Lilly and News

InvestorsObserver
Should Drug Manufacturers - General Stock Eli Lilly And Co (LLY) Be in Your Portfolio Thursday?.
InvestorsObserver,
9 hours ago
StreetInsider.com
Form 424B2 BARCLAYS BANK PLC.
StreetInsider.com,
14 hours ago
London South East
Investing.com UK
GuruFocus.com

Returns for LLY

Cumulative Returns on LLY

29.1%


10-Year Cumulative Returns

33.8%


7-Year Cumulative Returns

41.0%


5-Year Cumulative Returns

55.6%


3-Year Cumulative Returns

Risks for LLY

What is the probability of a big loss on LLY?

14.2%


Probability that Eli Lilly and stock will be more than 20% underwater in next one year

0%


Probability that Eli Lilly and stock will be more than 30% underwater in next one year.

0%


Probability that Eli Lilly and stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does LLY drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Eli Lilly and was unfortunately bought at previous high price.

Drawdowns

Financials for Eli Lilly and

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue6.6%29,51627,69128,54129,24029,07129,32328,31827,75926,72625,48624,54023,21422,95023,08722,32021,84321,67321,62221,49321,26220,916
  S&GA Expenses4.5%6,9326,6326,4406,3896,3536,4146,4326,3946,3856,1486,1216,2656,1096,2466,2146,2096,2546,1545,9755,3875,509
  R&D Expenses7.6%8,1407,5667,1917,0936,9966,8696,9316,7616,5216,2565,9765,8295,7455,7575,5955,4055,3055,1745,0514,8854,944
EBITDA-100.0%-7,7328,3298,1437,8428,3667,7038,2548,4228,5798,7067,8737,7717,5166,650------
EBITDA Margin-100.0%-0.28*0.29*0.28*0.27*0.29*0.27*0.30*0.32*0.34*0.35*0.34*0.34*0.33*0.30*------
Earnings Before Taxes15.9%7,2816,2836,8066,5506,2306,7336,1566,7856,9777,0267,2306,4246,3936,2155,2664,5344,4703,0463,6803,1402,391
EBT Margin-100.0%-0.23*0.24*0.22*0.21*0.23*0.22*0.24*0.26*0.28*0.29*0.28*0.28*0.27*0.24*------
Net Income14.3%6,4985,6876,2456,0335,6926,1295,5825,9726,0716,0936,1945,5735,6185,5338,3187,9487,8436,2563,232450-143
Net Income Margin-100.0%-0.21*0.22*0.21*0.20*0.21*0.20*0.22*0.23*0.24*0.25*0.24*0.24*0.24*0.37*------
Free Cashflow-100.0%-6,2927,0847,6617,1088,0637,2616,9197,0957,8156,5006,6486,3524,9084,837------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets3.1%54,81453,16349,49047,46247,06446,91948,80648,18747,80946,83846,63343,94641,96741,10339,28637,89338,66638,00743,90844,62542,359
  Current Assets2.5%21,33220,81118,03517,64017,11516,96518,45217,80817,29616,60517,46216,24014,58213,99413,71012,66213,45512,59820,55020,68618,333
    Cash Equivalents-24.0%2,6953,5462,0672,6172,6232,4593,8193,7883,2203,0023,6573,5952,3651,6992,338-2,2902,0367,3218,9606,817
  Inventory5.6%4,7994,5454,3103,8313,8993,8933,8863,9073,8253,6613,9803,5553,3143,1023,1913,1013,1813,0553,0984,1184,156
  Net PPE6.9%11,27710,54610,1449,3119,1289,1038,9858,9208,8568,6308,6828,2817,9817,8987,8737,8027,8487,7807,9968,8148,771
  Goodwill0.1%4,0794,0734,0733,8923,8923,8923,8923,8843,8843,8773,7673,7263,7233,7793,6793,7733,8203,8561,3674,358-
  Current Liabilities18.1%18,91516,01017,13815,65315,62113,38615,05313,68215,09311,71412,48211,97711,98912,61011,77510,82911,85511,23611,88810,82713,055
    LT Debt, Non Current-3.8%18,15818,88114,73814,14414,69215,15315,34615,52214,73716,20016,58716,33515,06413,98213,81813,66213,71813,6109,19611,6759,171
Shareholder's Equity-1.1%11,06411,19010,65010,0708,5459,3318,9797,7576,4446,8995,6424,8274,0933,0792,6073,3832,7812,4809,82913,07711,555
  Retained Earnings-2.5%10,36910,63910,04310,0078,5569,3698,9599,6398,5309,1817,8307,1546,6175,8794,9204,9824,3184,87911,39614,40914,247
  Additional Paid-In Capital2.3%6,9496,7936,9216,8296,7466,6566,8336,7586,6696,5796,7796,6996,6296,5566,6856,6096,5355,7576,5846,5235,826
Accumulated Depreciation1.4%10,63210,48610,23310,07410,12010,1389,9779,9639,8429,6439,5719,6019,2979,1429,1629,0558,9568,7928,6679,6729,566
Shares Outstanding-0.1%900901-901900904-907907909-907907908-914921980-1,0201,030
Minority Interest-18.2%86.0010512696.0011513117619721920118416917911892.0080.0077.0085.001,0801,07466.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-8.8%5,7416,2927,0847,6617,4948,0867,2616,9197,0957,8156,5006,6486,3524,9084,8374,3224,9335,3995,5255,8195,579
  Share Based Compensation17.3%471401371354359358343355337322308302306308312304297287280279280
Cashflow From Investing12.6%-2,545-2,912-3,261-2,780-2,859-2,516-2,762-3,057-2,754-2,481-2,258-1,626-1,736-1,465-8,082-8,700-8,674-5,6021,9064,2182,858
Cashflow From Financing-43.0%-3,025-2,116-5,406-5,791-4,991-5,951-4,131-3,896-3,712-4,302-3,137-2,959-4,373-3,585-2,324-2,850-725-670-5,904-4,807-4,739
  Dividend Payments3.7%3,8023,6683,5363,4253,3133,1983,0872,9842,8852,7912,6872,6042,5202,4442,4102,3952,3802,3622,3122,2882,263
  Buy Backs0%7507501,5002,2502,2502,7501,250500500-5008001,4001,4004,4005,2005,6006,5514,1513,1512,151

LLY Income Statement

2023-06-30
Consolidated Condensed Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Revenue (Note 2)$ 8,312.1$ 6,488.0$ 15,272.1$ 14,298.0
Costs, expenses, and other:    
Cost of sales1,807.41,430.53,434.13,502.6
Research and development2,356.51,781.94,341.63,392.0
Marketing, selling, and administrative1,925.41,625.13,674.63,183.0
Acquired in-process research and development (Note 3)97.1440.4202.1606.0
Other–net, (income) expense (Note 10)36.8119.21.1469.9
Costs, expenses, and other6,223.25,397.111,653.511,153.5
Income before income taxes2,088.91,090.93,618.63,144.5
Income taxes (Note 6)325.7138.4510.5289.1
Net income$ 1,763.2$ 952.5$ 3,108.1$ 2,855.4
Earnings per share:    
Basic (in dollars per share)$ 1.96$ 1.06$ 3.45$ 3.17
Diluted (in dollars per share)$ 1.95$ 1.05$ 3.44$ 3.16
Shares used in calculation of earnings per share:    
Basic (in shares)899.7900.3900.3902.0
Diluted (in shares)902.7902.9903.0904.4

LLY Balance Sheet

2023-06-30
Consolidated Condensed Balance Sheets - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current Assets  
Cash and cash equivalents (Note 5)$ 2,694.5$ 2,067.0
Short-term investments (Note 5)134.6144.8
Accounts receivable, net of allowances of $13.8 (2023) and $16.0 (2022)7,516.16,896.0
Other receivables1,655.31,662.9
Inventories4,798.74,309.7
Prepaid expenses and other current assets4,532.42,954.1
Total current assets21,331.618,034.5
Investments (Note 5)2,745.12,901.8
Goodwill4,078.94,073.0
Other intangibles, net6,903.57,206.6
Deferred tax assets3,805.92,792.9
Property and equipment, net of accumulated depreciation of $10,631.6 (2023) and $10,233.4 (2022)11,277.410,144.0
Other noncurrent assets4,671.64,337.0
Total assets54,814.049,489.8
Current Liabilities  
Short-term borrowings and current maturities of long-term debt661.61,501.1
Accounts payable2,474.21,930.6
Employee compensation867.71,059.8
Sales rebates and discounts10,389.98,784.1
Dividends payable1,016.21,017.2
Income taxes payable1,233.8475.1
Other current liabilities2,271.62,370.3
Total current liabilities18,915.017,138.2
Other Liabilities  
Long-term debt18,158.414,737.5
Accrued retirement benefits (Note 7)1,308.81,305.1
Long-term income taxes payable3,330.73,709.6
Other noncurrent liabilities1,951.81,824.0
Total other liabilities24,749.721,576.2
Commitments and Contingencies (Note 8)
Eli Lilly and Company Shareholders' Equity  
Common stock593.6594.1
Additional paid-in capital6,948.66,921.4
Retained earnings10,368.510,042.6
Employee benefit trust(3,013.2)(3,013.2)
Accumulated other comprehensive loss (Note 9)(3,788.7)(3,844.6)
Cost of common stock in treasury(45.0)(50.5)
Total Eli Lilly and Company shareholders' equity11,063.810,649.8
Noncontrolling interests85.5125.6
Total equity11,149.310,775.4
Total liabilities and equity$ 54,814.0$ 49,489.8
David A. Ricks
35000
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.